HLB Pep Co., Ltd.
Peptide biomaterials and CDMO services provider developing novel peptide-based drug candidates such as leuprorelin and desmopressin.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2000 and listed on KOSDAQ in 2016, HLB Pep is a peptide biomaterials and novel drug candidate development company. It provides leuprorelin (prostate cancer, precocious puberty treatment) and desmopressin (type 1 diabetes, nocturnal enuresis treatment) as pharmaceutical-use peptides, along with custom research-use peptides and CDMO services. Revenue is split between research-use peptide materials at 54.85% (custom peptides 54.19%) and pharmaceutical-use peptide materials at 37.67% (desmopressin 19.97%, contract services 7.22%, leuprorelin 4.92%).
Products & technology
- LeuprorelinProstate cancer, precocious puberty treatment
- DesmopressinType 1 diabetes, nocturnal enuresis treatment
- Catalog PeptideResearch-use peptide material supply
- CDMO investigational drug manufacturingClinical/non-clinical contract manufacturing, process and specification development
R&D and key agreements
Source: DART corporate disclosure항균 펩타이드 · Part of new drug candidate pipeline
암 표적능 펩타이드 · 암 · Part of new drug candidate pipeline
당뇨/비만치료 펩타이드 · 당뇨, 비만 · Part of new drug candidate pipeline
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition